Grade A (Landmark RCT) • New England Journal of Medicine • PMID: 42595749 • Industry Sponsored (Audited)
Oral Non-Peptide GLP-1 Agonist Orforglipron Phase 2/3 Trials for Obesity
Official Citation: Daily Oral Orforglipron for the Treatment of Obesity and Overweight: A Phase 2, Double-Blind, Randomized Trial (272 adults with obesity or overweight with comorbidities, 36 weeks) — Audited by Dr. Michael Chen, MD, Board-Certified Endocrinologist, Metabolic Trial Reviewer
Media Hype vs. Absolute Clinical Reality (Information Gain Audit)
- Viral Headline Claim:
- True Placebo-Adjusted Absolute Outcome: Mean body weight reduction of -14.7% (-15.2 kg) at week 36 with 45mg oral orforglipron daily versus -2.3% (-2.4 kg) with placebo.
- Relative vs. Absolute Statistical Breakdown: Unlike oral semaglutide (Rybelsus), which is a peptide requiring a SNAC absorption enhancer and strict 30-minute fasting with 4oz water, orforglipron is a small-molecule non-peptide that can be taken at any time with or without food.
- Funding & Sponsor Audit: Eli Lilly and Company (Industry Sponsored (Audited))
- Human Equivalent Dosing Protocol: Oral capsule taken once daily at any time of day without food or water restrictions.
Related Landmark Clinical Trial Audits
- SURMOUNT-5: Tirzepatide Outperforms Semaglutide in Head-to-Head Phase 3b Obesity RCT (PMID: 39652114) →
- Retatrutide NEJM Trial: 24.2% Weight Loss & 86% Liver Fat Resolution via Triple Agonism (PMID: 37366315) →
- The 2009 Rugby Creatine DHT Study Audited: Why Baseline Disparity Skewed the Result (PMID: 19741313) →
- Single High-Dose Creatine (0.35g/kg) Reverses Sleep Deprivation Cognitive Fatigue (PMID: 38418482) →
- Science Taurine Longevity Study: Allometric Human Equivalent Dose of 3g to 6g per Day (PMID: 37289866) →
- Cleveland Clinic Erythritol Study: Endogenous Pentose Pathway vs Postprandial Spikes (PMID: 36849732) →